Most clinical trials were conducted on a thoroughly selected population of patients with mainly clear-cell metastatic renal-cell carcinoma (mRCC) without brain metastases and with a good somatic status.

In routine clinical practice, the population of patients with mRCC is more heterogeneous: there are patients who have, in addition to the most common clear-cell mRCC, non-clear-cell mRCC, brain metastases and a somatic ECOG score of > 1. Undoubtedly, practitioners have a concern in the efficiency, tolerance, and expediency of using target drugs in all groups of patients with mRCC. This review gives a number of drugs approved for the treatment of mRCC and analyzes criteria for their choice.

Source: Alekseev B.Ya., Kalpinsky A.S. EFFICIENCY OF TARGETED THERAPY USED IN THE HETEROGENEOUS POPULATION OF PATIENTS WITH METASTATIC KIDNEY CANCER. Cancer Urology. 2012;8(3):37-42. (In Russ.) https://doi.org/10.17650/1726-9776-2012-8-3-37-42